Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the d
GripAble has raised $11 million in first-round financing that will be used to advance its digital health approach to rehabilitation for people with neurological and musculoskeletal conditio
The largest-ever study of genetics in Alzheimer's disease patients has identified 42 new genes that appear to be linked to the neurodegenerative disorder.
By a narrow margin, an FDA advisory committee has voted against approval of Amylyx' experimental medicine for amyotrophic lateral sclerosis until the company can provide more evidence that
After months of debate about the validity of its phase 3 clinical trials for Alzheimer's therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to l
Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer's therapy Aduhelm, handing over full responsibility to its US counterpart.